Madrigal Pharmaceuticals, Inc. (MDGL)
534.49
+1.37
(+0.26%)
USD |
NASDAQ |
Sep 11, 16:00
534.04
-0.45
(-0.08%)
After-Hours: 20:00
Madrigal Pharmaceuticals Enterprise Value : 11.85B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 11.85B |
| September 10, 2026 | 11.82B |
| September 09, 2026 | 12.13B |
| September 08, 2026 | 11.84B |
| September 04, 2026 | 12.00B |
| September 03, 2026 | 12.04B |
| September 02, 2026 | 12.14B |
| September 01, 2026 | 11.95B |
| August 31, 2026 | 11.98B |
| August 28, 2026 | 11.84B |
| August 27, 2026 | 12.06B |
| August 26, 2026 | 11.95B |
| August 25, 2026 | 11.34B |
| August 24, 2026 | 11.33B |
| August 21, 2026 | 11.44B |
| August 20, 2026 | 11.50B |
| August 19, 2026 | 11.98B |
| August 18, 2026 | 11.62B |
| August 17, 2026 | 11.63B |
| August 14, 2026 | 11.23B |
| August 13, 2026 | 11.23B |
| August 12, 2026 | 11.89B |
| August 11, 2026 | 11.87B |
| August 10, 2026 | 11.41B |
| August 07, 2026 | 11.29B |
| Date | Value |
|---|---|
| August 06, 2026 | 11.30B |
| August 05, 2026 | 11.38B |
| August 04, 2026 | 11.23B |
| August 03, 2026 | 10.64B |
| July 31, 2026 | 10.30B |
| July 30, 2026 | 10.90B |
| July 29, 2026 | 12.14B |
| July 28, 2026 | 11.95B |
| July 27, 2026 | 12.24B |
| July 24, 2026 | 12.08B |
| July 23, 2026 | 12.06B |
| July 22, 2026 | 11.93B |
| July 21, 2026 | 12.14B |
| July 20, 2026 | 11.88B |
| July 17, 2026 | 12.29B |
| July 16, 2026 | 12.11B |
| July 15, 2026 | 12.22B |
| July 14, 2026 | 11.91B |
| July 13, 2026 | 11.77B |
| July 10, 2026 | 11.90B |
| July 09, 2026 | 12.44B |
| July 08, 2026 | 12.57B |
| July 07, 2026 | 12.10B |
| July 06, 2026 | 11.74B |
| July 02, 2026 | 11.70B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| Exelixis, Inc. | 13.29B |
| United Therapeutics Corp. | 18.55B |
| Karyopharm Therapeutics, Inc. | 227.60M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.94M |
| Revenue (Quarterly) | 364.25M |
| Total Expenses (Quarterly) | 422.19M |
| EPS Diluted (Quarterly) | -1.988 |
| Gross Profit Margin (Quarterly) | 88.91% |
| Profit Margin (Quarterly) | -15.91% |
| Earnings Yield | -2.41% |
| Normalized Earnings Yield | -2.394 |